No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
samsungbiologics.comNo one on the platform currently holds 207940.KS.
No tracked institution reports a position in 207940.KS as of their last filing.
No one on the platform has traded 207940.KS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.6% | 9.8% | — | — | — | |
| Rev. Growth % | 30.3% | 31.4% | ||||
| Profit Margin % | 39.2% | 29.0% | 15.6% | |||
| Free Cash Flow Margin % | 18.8% | 8.5% | -19.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.45T | -4.8% | $41306.97 | $40558.16–$43448.72 | — | 20 |
| 2027 | $6.35T | +16.4% | $48999.28 | $46421.85–$55330.43 | — | 21 |
| 2028 | $7.11T | +12.0% | $54964.64 | $52752.81–$59260.12 | — | 18 |
| 2029 | $7.72T | +8.6% | $0.00 | $0.00–$0.00 | — | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $9419.84 | $9314.54 | -1.1% |
| 2026-04-22 | $9544.89 | $9924.66 | +4.0% |
| 2026-01-21 | $11295.21 | $10935.49 | -3.2% |
| 2025-10-28 | $9893.27 | $9019.71 | -8.8% |
| 2025-07-23 | $6771.20 | $4618.91 | -31.8% |
| 2025-04-23 | $4275.14 | $5127.11 | +19.9% |
| 2025-01-22 | $3741.23 | $4340.97 | +16.0% |
| 2024-10-23 | $3434.36 |
| $3716.00 |
| +8.2% |
| $8700.00 |
| +0.00% |
| $340.0B |
| — |
| 085660.KQChabiotech Co.,Ltd. | $7950.00 | +0.13% | $735.4B | — |
| 087010.KQPeptron, Inc. | $150800.00 | +8.41% | $3.51T | — |
Source: Financial Modeling Prep · peers by sector/industry